A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression

Trial Profile

A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Postnatal depression
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Magnolia
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2018 According to a Marinus Pharmaceuticals media release, Company has increased targeted enrollment in this study.This increase in study scope and the corresponding forecast for patient recruitment have extended our expected timing for completion of the first part to the third quarter of 2018.
    • 06 Mar 2018 According to a Marinus Pharmaceuticals media release, data is expected third quarter 2018.
    • 05 Mar 2018 Planned number of patients changed from 30 to 60.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top